Victoria Taylor‐Bateman

This study uses Mendelian randomisation to assess if diabetes drug targets affect vascular dementia risk, finding no strong evidence but a suggestive protective effect for DPP4 inhibition.

This study uses pQTL-based Mendelian randomization and colocalization to assess if DMARD targets reduce Alzheimer's disease risk, finding only FCGR3B shows increased risk with higher plasma levels.

This study investigates whether blood pressure interacts with genetic risk of dementia to influence dementia diagnosis, finding that higher systolic blood pressure increases dementia risk regardless of genetic predisposition.

This study identifies causes and consequences of vascular dementia using polygenic risk scores, phenome-wide association, and Mendelian randomization analyses from UK Biobank data, highlighting cardiometabolic and educational factors as key modifiable risks.

This paper uses Mendelian randomization to assess if existing drugs targeting lipid-lowering, anti-hypertensive, or anti-inflammatory pathways affect vascular dementia risk, finding potential benefits for beta-1 adrenergic receptor antagonists and risks for ACE inhibitors.